Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Theodore Daly

Garden City, NY Medical Doctor

NPI 1518965441 CMS profile 341457

901 Stewart Ave, Suite 201, Garden City, NY 11530

Open in the dashboard

General payments

$480,034

1,093 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,016 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Theodore Daly of Garden City, NY is reported in the CMS Open Payments database as having received $480,034 across 1,093 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,016 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,082 151
2024 General $127,690 219
2023 General $95,238 205
2022 General $90,206 160
2021 General $39,251 99
2020 General $45,540 98
2019 General $43,028 161

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Daly
  • New York median
  • Middle half of New York
  • National median

In program year 2025, general payments to Theodore Daly were reported at $39,082. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.

Show as a table
Year Theodore Daly New York median Middle half National median
2019 $43,028 $175 $53–$665 $163
2020 $45,540 $122 $37–$426 $114
2021 $39,251 $144 $44–$514 $132
2022 $90,206 $160 $51–$578 $149
2023 $95,238 $170 $54–$593 $160
2024 $127,690 $173 $56–$618 $164
2025 $39,082 $180 $58–$640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $128,083 163 payments
  2. Lilly USA, LLC $120,269 114 payments
  3. Amgen Inc. $113,393 169 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $39,680 28 payments
  5. Celgene Corporation $20,742 31 payments
  6. AbbVie, Inc. $18,758 83 payments
  7. E.R. Squibb & Sons, L.L.C. $12,458 62 payments
  8. Sun Pharmaceutical Industries Inc. $5,678 34 payments
  9. Arcutis Biotherapeutics, Inc. $4,466 36 payments
  10. Genzyme Corporation $3,656 30 payments
  11. Other $12,851 343 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $367,635 139 payments
  2. Consulting Fee $49,909 15 payments
  3. Travel and Lodging $32,562 120 payments
  4. Food and Beverage $24,725 798 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,960 1 payment
  6. Education $1,242 20 payments
Products named General payments · program years 2019–2025
  1. Otezla Inflammation $113,355 168 payments
  2. OLUMIANT $111,878 78 payments
  3. CIBINQO $90,195 126 payments
  4. SPEVIGO $39,307 25 payments
  5. Otezla Dermatology $20,686 23 payments
  6. EUCRISA $19,706 79 payments
  7. RINVOQ $18,146 50 payments
  8. LITFULO $15,471 51 payments
  9. Leqselvi $5,270 17 payments
  10. Zoryve $4,301 24 payments
  11. Other $21,062 577 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,645

Median for Dermatology: 534

Drug cost

$532,697

Median for Dermatology: $67,151

Branded share of claims

7.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 55 $168,751
Otezla Apremilast Brand 24 $148,253
Dupixent Pen Dupilumab Brand 19 $76,262
Jublia Efinaconazole Brand 27 $37,285
Zoryve Roflumilast Brand 33 $29,264
Tacrolimus Generic 70 $13,159
Minoxidil Generic 822 $8,603
Dutasteride Generic 198 $6,167
Clobetasol Propionate Generic 114 $5,260
Spironolactone Generic 435 $5,031

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$1,201,497

Of which drugs: $17,088

Medicare patients

1,217

Average age 74

Services billed

23,869

857 women, 360 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 53%
Ischemic heart disease 27%
Diabetes 26%
Osteoporosis 23%
Cancer 17%
Depression 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 31 11,402 $15,295
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 134 409 $312
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 56 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OLUMIANT
$48,741 — —
SPEVIGO
$29,989 — —
RINVOQ
$17,593 — —
CIBINQO
$16,296 — —
LITFULO
$9,427 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,093 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record